Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

BACKGROUND: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and elevated cardiovascular risk. The comparative effects among parti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Circulation
Autors principals: Mahaffey, Kenneth W., Neal, Bruce, Perkovic, Vlado, de Zeeuw, Dick, Fulcher, Greg, Erondu, Ngozi, Shaw, Wayne, Fabbrini, Elisa, Sun, Tao, Li, Qiang, Desai, Mehul, Matthews, David R.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2018
Matèries:
Original Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5777572/
https://ncbi.nlm.nih.gov/pubmed/29133604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.117.032038
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars